Unicycive Therapeutics Inc (UNCY) Stock Price, Quote & News

Company Profile

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, li...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 351 4495

Website: unicycive.com

Address:

4300 El Camino Real, Suite 210, Los Altos, United States

Eliteh Jun. 17 at 8:07 PM

$UNCY A 1M share buy AH...

1 · Reply

Murfdog1968 Jun. 17 at 7:28 PM

$UNCY

0 · Reply

TwongStocks Jun. 17 at 7:25 PM

$UNCY NASDAQ Equity Corporate Actions Alert # 2025 - 316 Information Regarding the Reverse Stock Split and CUSIP Number Change for Unicycive Therapeutics, Inc. (UNCY) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-316 Unicycive Therapeutics, Inc. (UNCY) will effect a one-for-ten (1-10) reverse split of its Common Stock. The reverse stock split will become effective on Friday, June 20, 2025. In conjunction with the reverse split, the CUSIP number will change to 90466Y202.

0 · Reply

CliffordCapital Jun. 17 at 7:10 PM

$PLX reminds be of $UNCY when they moved it down to 0,20$ cents before it went to >1$.. max pain to get retail into selling. 🤣

1 · Reply

JDubbs530 Jun. 17 at 6:43 PM

$UNCY sooooo RS Possible dilution? And a CRL? I’m I reading this right?

0 · Reply

boomshiva Jun. 17 at 6:26 PM

$UNCY Nibbled just a little more to round it up to an even number after RS. $0.63 cost basis.

0 · Reply

DouglasJanes2025 Jun. 17 at 5:40 PM

$UNCY Alright here’s a positive spin on RS! The RS technically lowers the float. Meaning that the spike after FDA approval could be even greater than it would’ve otherwise been. Is this why management didn’t put much effort into preventing RS? Probably not. That’s too conspiratorial BUT it could be a happy accident…

1 · Reply

Quaestus_ Jun. 17 at 5:37 PM

$UNCY What I think is the following: The FDA flagged them for CMC issues and labelling talks were precluded (news released June 10th). This is FDA speak for, "We aren't going to approve you please try again next year.". When labelling talks are not initiated ~90% of applications receive a CRL. So given we got this reverse short of 10/1 UNCY is bracing for the rejection impact so they can stay compliant with listing, and/or when they get rejected they will submit an offering to raise money for the submission of another application. I think it's best to sell and get back in a few months from now.

1 · Reply

roger_eva Jun. 17 at 5:07 PM

$UNCY this is a BO target.

1 · Reply

zawojak Jun. 17 at 5:05 PM

$UNCY 250k wall at $0.69 impossible to break today imho

0 · Reply

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

Jun 10, 2025, 6:00 AM EDT - 8 days ago

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

May 22, 2025, 7:00 AM EDT - 26 days ago

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 21, 2025, 7:00 AM EDT - 27 days ago

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 14, 2025, 7:15 AM EDT - 4 weeks ago

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Apr 1, 2025, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 2 months ago

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 7:00 AM EDT - 3 months ago

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

Feb 20, 2025, 7:00 AM EST - 4 months ago

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

Jan 28, 2025, 7:00 AM EST - 5 months ago

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Jan 7, 2025, 7:00 AM EST - 5 months ago

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Nov 21, 2024, 7:00 AM EST - 7 months ago

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 7:15 AM EST - 7 months ago

Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 7 months ago

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Oct 28, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 16, 2024, 4:35 PM EDT - 8 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024

Oct 14, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024

Oct 9, 2024, 7:03 AM EDT - 8 months ago

Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

Sep 24, 2024, 7:03 AM EDT - 9 months ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Sep 16, 2024, 7:03 AM EDT - 9 months ago

Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024

Sep 5, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Aug 26, 2024, 7:03 AM EDT - 10 months ago

Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024

Aug 14, 2024, 7:10 AM EDT - 10 months ago

Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 7:03 AM EDT - 11 months ago

Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)

Jul 11, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Jul 10, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)

Jul 1, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Joins Russell Microcap® Index

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial

May 28, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

May 23, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

May 15, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

May 13, 2024, 4:16 PM EDT - 1 year ago

Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update

Apr 10, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Mar 28, 2024, 4:15 PM EDT - 1 year ago

Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update

Mar 25, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress

Mar 14, 2024, 7:03 AM EDT - 1 year ago

Unicycive Announces $50 Million Private Placement

Mar 13, 2024, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference

Mar 7, 2024, 4:12 PM EST - 1 year ago

Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)

Mar 4, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

Feb 14, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

Jan 29, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

Jan 23, 2024, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Dec 18, 2023, 7:03 AM EST - 1 year ago

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

Nov 29, 2023, 7:03 AM EST - 1 year ago

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

Nov 14, 2023, 4:15 PM EST - 1 year ago

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 23, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

Sep 6, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

Aug 29, 2023, 7:03 AM EDT - 1 year ago

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

Aug 14, 2023, 5:36 PM EDT - 2 years ago

Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update

Eliteh Jun. 17 at 8:07 PM

$UNCY A 1M share buy AH...

1 · Reply

Murfdog1968 Jun. 17 at 7:28 PM

$UNCY

0 · Reply

TwongStocks Jun. 17 at 7:25 PM

0 · Reply

CliffordCapital Jun. 17 at 7:10 PM

$PLX reminds be of $UNCY when they moved it down to 0,20$ cents before it went to >1$.. max pain to get retail into selling. 🤣

1 · Reply

JDubbs530 Jun. 17 at 6:43 PM

$UNCY sooooo RS Possible dilution? And a CRL? I’m I reading this right?

0 · Reply

boomshiva Jun. 17 at 6:26 PM

$UNCY Nibbled just a little more to round it up to an even number after RS. $0.63 cost basis.

0 · Reply

DouglasJanes2025 Jun. 17 at 5:40 PM

1 · Reply

Quaestus_ Jun. 17 at 5:37 PM

1 · Reply

roger_eva Jun. 17 at 5:07 PM

$UNCY this is a BO target.

1 · Reply

zawojak Jun. 17 at 5:05 PM

$UNCY 250k wall at $0.69 impossible to break today imho

0 · Reply

Bullvbearss Jun. 17 at 4:39 PM

$UNCY I'm going all in

1 · Reply

roger_eva Jun. 17 at 4:27 PM

$UNCY

0 · Reply

roger_eva Jun. 17 at 4:16 PM

$UNCY r/s technically wont change mc, which is currenlybless thsn 100m. A blokbuster drug can generate hundreds of millions of dollars and mc should a billion. So 1000% increase poential from here if approved

0 · Reply

w66hill Jun. 17 at 3:42 PM

$UNCY waiting to add but this is definitely as good as a RS could be... 10 to 1. Very rare for a management team to do that low to regain compliance.

0 · Reply

DouglasJanes2025 Jun. 17 at 3:38 PM

$UNCY why is it always hard with UNCY? So little upside for so much pain.

0 · Reply

JDubbs530 Jun. 17 at 3:19 PM

$UNCY more bad news drop?

1 · Reply

Eliteh Jun. 17 at 2:58 PM

$UNCY I'll also add, as of now this stock has been given every opportunity to fall off a cliff, and it continually seems to be fighting its way up

1 · Reply

Eliteh Jun. 17 at 2:55 PM

$UNCY As mentioned, im closely watching UNCY still. A RS was already guaranteed after the FDA update. Analysts are already anticipating a CRL, but the question is how many months delay now... 2/3 or 9? If 2/3, than this RS is a nothing burger and you best believe institutions are buying on these down days. If 9 months, completely different story, and UNCY is in a bit more trouble. Keep in mind, 2/3 months most likely doesnt mean dilution, so RS is neutral in that regard, that they wouldn't be doing it as an intent to dilute but only for minimum bid

0 · Reply

KING_OF_BIO Jun. 17 at 2:51 PM

$UNCY Said it once, I'll say it again. RS isn't always a bad thing...

0 · Reply

DouglasJanes2025 Jun. 17 at 2:36 PM

$UNCY RS ends the party. If they even spent 10k on PR they would’ve got this stick to $1 yonks ago. Arrogance and incompetence merged into one company.

2 · Reply

Str8upPsych0 Jun. 17 at 2:28 PM

$UNCY shes fighting for us !

0 · Reply

DouglasJanes2025 Jun. 17 at 1:58 PM

$UNCY why did this drop 20% on open today?

1 · Reply

Market Cap	90.47M
Revenue (ttm)	0.00
Net Income (ttm)	-36.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	11,049,999
Avg Vol	3,318,034
Day's Range	N/A - N/A
Shares Out	120.63M
Stochastic %K	34%
Beta	2.01
Analysts	Strong Sell
Price Target	$5.71